27271951|t|Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
27271951|a|Paraneoplastic encephalitides usually precede a diagnosis of cancer and are often refractory to immunosuppressive therapy. Conversely, autoimmune encephalitides are reversible conditions that can occur in the presence or absence of cancer. To report the induction of autoimmune encephalitis in 2 patients after treatment of metastatic cancer with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab. A retrospective case study was conducted of the clinical and management course of 2 patients with progressive, treatment - refractory metastatic cancer who were treated with a single dose each (concomitantly) of the immune checkpoint inhibitors nivolumab, 1 mg/kg, and ipilimumab, 3 mg/kg. Nivolumab and ipilimumab. The clinical response to immunosuppressive therapy in suspected autoimmune encephalitis in the setting of immune checkpoint inhibitor use. Autoantibody testing confirmed identification of anti-N-methyl-D-aspartate receptor antibodies in the cerebrospinal fluid of 1 patient. Withdrawal of immune checkpoint inhibitors and initiation of immunosuppressive therapy, consisting of intravenous methylprednisolone sodium succinate equivalent to 1000 mg of methylprednisolone for 5 days, 0.4 mg/kg/d of intravenous immunoglobulin for 5 days, and 2 doses of rituximab, 1000 mg, in 1 patient and oral prednisone, 60 mg/d, in the other patient, resulted in improved neurologic symptoms. Immune checkpoint inhibition may favor the development of immune responses against neuronal antigens, leading to autoimmune encephalitis. Early recognition and treatment of autoimmune encephalitis in patients receiving immune checkpoint blockade therapy will likely be essential for maximizing clinical recovery and minimizing the effect of drug-related toxic effects. The mechanisms by which immune checkpoint inhibition may contribute to autoimmune encephalitis require further study.
27271951	15	38	Autoimmune Encephalitis	T038	UMLS:C0393639
27271951	53	80	Immune Checkpoint Inhibitor	T103	UMLS:C1254351
27271951	95	112	Metastatic Cancer	T038	UMLS:C0027627
27271951	113	142	Paraneoplastic encephalitides	T038	UMLS:C0338430
27271951	161	180	diagnosis of cancer	T058	UMLS:C0920688
27271951	209	234	immunosuppressive therapy	T058	UMLS:C0021079
27271951	248	273	autoimmune encephalitides	T038	UMLS:C0393639
27271951	322	330	presence	T033	UMLS:C0150312
27271951	345	351	cancer	T038	UMLS:C0006826
27271951	380	403	autoimmune encephalitis	T038	UMLS:C0393639
27271951	437	454	metastatic cancer	T038	UMLS:C0027627
27271951	481	509	immune checkpoint inhibitors	T103	UMLS:C1254351
27271951	510	519	nivolumab	T103	UMLS:C3657270
27271951	524	534	ipilimumab	T103	UMLS:C1367202
27271951	538	562	retrospective case study	T062	UMLS:C0035363
27271951	584	607	clinical and management	T058	UMLS:C1516615
27271951	659	687	refractory metastatic cancer	T038	UMLS:C0677936
27271951	697	709	treated with	T058	UMLS:C0332293
27271951	752	780	immune checkpoint inhibitors	T103	UMLS:C1254351
27271951	781	790	nivolumab	T103	UMLS:C3657270
27271951	805	815	ipilimumab	T103	UMLS:C1367202
27271951	826	835	Nivolumab	T103	UMLS:C3657270
27271951	840	850	ipilimumab	T103	UMLS:C1367202
27271951	856	873	clinical response	T033	UMLS:C4055223
27271951	877	902	immunosuppressive therapy	T058	UMLS:C0021079
27271951	916	939	autoimmune encephalitis	T038	UMLS:C0393639
27271951	958	985	immune checkpoint inhibitor	T103	UMLS:C1254351
27271951	991	1011	Autoantibody testing	T058	UMLS:C1272321
27271951	1012	1021	confirmed	T033	UMLS:C0750484
27271951	1040	1085	anti-N-methyl-D-aspartate receptor antibodies	T103	UMLS:C3203613
27271951	1093	1112	cerebrospinal fluid	T031	UMLS:C0007806
27271951	1141	1169	immune checkpoint inhibitors	T103	UMLS:C1254351
27271951	1188	1213	immunosuppressive therapy	T058	UMLS:C0021079
27271951	1348	1374	intravenous immunoglobulin	T103	UMLS:C0085297
27271951	1402	1411	rituximab	T103	UMLS:C0393022
27271951	1499	1507	improved	T033	UMLS:C0184511
27271951	1508	1527	neurologic symptoms	T033	UMLS:C0235031
27271951	1529	1557	Immune checkpoint inhibition	T038	UMLS:C2255931
27271951	1587	1603	immune responses	T038	UMLS:C0301872
27271951	1642	1665	autoimmune encephalitis	T038	UMLS:C0393639
27271951	1702	1725	autoimmune encephalitis	T038	UMLS:C0393639
27271951	1748	1782	immune checkpoint blockade therapy	T058	UMLS:C0021079
27271951	1922	1950	immune checkpoint inhibition	T038	UMLS:C2255931
27271951	1969	1992	autoimmune encephalitis	T038	UMLS:C0393639